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We genotyped 525 independent North American white individuals with systemic lupus erythematosus (SLE) for the
PTPN22 R620W polymorphism and compared the results with data generated from 1,961 white control individuals.
The R620W SNP was associated with SLE (genotypic ), with estimated minor (T) allele frequencies ofPp .00009
12.67% in SLE cases and 8.64% in controls. A single copy of the T allele (W620) increases risk of SLE (odds
ratio ; 95% conﬁdence interval [CI] 1.07–1.75), and two copies of the allele more than double this[OR]p 1.37
risk ( ; 95% CI 1.98–9.65). Together with recent evidence showing association of this SNP with typeORp 4.37
1 diabetes and rheumatoid arthritis, these data provide compelling evidence that PTPN22 plays a fundamental role
in regulating the immune system and the development of autoimmunity.
Systemic lupus erythematosus (SLE [MIM 152700]) is a
chronic and severe systemic autoimmune disease asso-
ciated with high titers of antinuclear antibodies and clini-
cal involvement of many different organs and tissues,
including skin, kidney, lungs, heart, and brain. SLE af-
fects ∼0.1% of the North American population, and
women are nearly 10 times more frequently affectedwith
disease than men. Epidemiologic evidence, together with
recent linkage and association studies, suggest that SLE
susceptibility in humans is strongly inﬂuenced by genetic
factors (Wakeland et al. 2001). Similarly, studies of lu-
pus-prone mice demonstrate the importance of genes in
driving the onset, progression, and end-organ targeting
of SLE (Wakeland et al. 2001). Abnormalities in B and
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T lymphocytes are found frequently in patientswith SLE,
and many studies have documented defects in proximal
signal transduction downstream of the T- (TCR) and B-
cell receptors (Kammer et al. 2002; Khan et al. 2003).
Begovich and colleagues (2004) recently discovered that
a missense polymorphism (rs2476601; 1858CrT) in pro-
tein tyrosine phosphatase N22 (PTPN22, a key molecule
regulating TCR signaling in memory/effector T lympho-
cytes [Hasegawa et al. 2004]), was strongly associated
with human rheumatoid arthritis (RA). The polymor-
phism occurs in the proximal proline-rich SH3-binding
domain of PTPN22, which results in substitution of a
highly conserved arginine with tryptophan (R620W).
This proline-rich region is an important docking site for
C-terminal Src tyrosine kinase (CSK) (Cloutier and Veil-
lette 1996), a molecule that downmodulates TCR sig-
naling by phosphorylating regulatory tyrosines on the
Src family kinase Lck (Cloutier and Veillette 1999). In
vitro experiments show that the R620W polymorphism
affects the ability of PTPN22 to bind CSK (Begovich et
al. 2004; Bottini et al. 2004). Since this SNP has also
independently been associated with type 1 diabetes (T1D)
(Bottini et al. 2004) and previous data have linked deﬁ-
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ciency in phosphatase activity with lupus in mice (Schultz
et al. 1993; O’Keefe et al. 1996; Di Cristofano et al.
1999), we investigated association of the R620W SNP
with SLE.
Initially, we compared R620W genotype frequencies of
cohort A, in which a single subject with SLE was ran-
domly selected from each of 185 white families with
SLE-affected sib pairs from the University of Minnesota
collection (Gaffney et al. 2000), with results generated
from926white controls (control 1) (Begovich et al. 2004).
The C/T genotype was observed in 38 of 185 (20.5%)
SLE cases and the T/T genotype in 6 (3.2%) cases (table
1). Compared with controls, the C/T and T/T genotypes
were signiﬁcantly overrepresented in the SLE cases
( , Fisher’s exact test). Similar results were ob-Pp .0109
tained when genotypes from a second affected subject
from the families were examined and compared with the
same controls (cohort B; ; C/T 16.1%,T/T4.4%;np 180
). In these two sample sets, the presence ofPp .0060
the T allele increased the odds of SLE by 1.46 (cohort
A) and 1.10 (cohort B). Although we emphasize the need
for caution in drawing conclusions from these results
because of the limited number of genotypes, the odds
ratios (ORs) for T/T homozygotes were 3.66 in cohort
A and 4.81 in cohort B and were signiﬁcant in a recessive
model (table 1).
We then conﬁrmed this ﬁnding using two independent
replication cohorts. The ﬁrst was a collection of 201white
individuals with SLE (cohort C), recruited at the Uni-
versity of Minnesota, from across North America as part
of a trio family collection. Overall, this group showed
very comparable PTPN22 R620W genotype frequencies
(22.3% C/T and 1.0% T/T) to those observed in cohorts
A and B. We also tested allele frequencies in a second
independent control group (control 2 [ ]),np 1,035
which showed very similar allele frequencies compared
with the control 1 group. When cohort C was compared
with the control 2 group, association of the SNP with
SLE was signiﬁcant ( ). A second replicationPp .0356
group was an independent collection of 139 whites with
SLE (cohort D), derived from the Hopkins Lupus Cohort
(Petri 2000). Again, the R620W genotypic frequencies
observed ( ; 17.3% C/T, 3.6% T/T) were verynp 139
comparable to those from the Minnesota cohorts; when
comparedwith the control 2 frequencies, theR620WSNP
was associated with SLE ( ).Pp .0015
Combination of data from the various independent case
cohorts and comparison with the controls provided us
with increased precision in our estimates of effect size
and statistical power for testing the hypothesized rela-
tionship between R620W and SLE. Joint analysis of co-
horts A, C, and D (525 individuals with SLE) yielded the
following estimates for SLE genotype frequencies: 20.4%
C/T, 2.5% T/T ( ; compared with the com-Pp .00009
bined control groups: 16.1% C/T and 0.6% T/T). Ex-
amination of the ORs in the combined data set again
suggested a dose effect, with heterozygotes at increased
risk relative to C/C homozygotes ( ; 95% CIORp 1.37
1.07–1.75) and T/T homozygotes, with more than twice
the risk of heterozygotes ( ; 95% CI 1.98–ORp 4.37
9.65). Very similar results were obtained when cohorts B,
C, and Dwere combined and analyzed together (BCD
[table 1]).
The overall risk-allele frequency of R620W in 525
individuals with SLE (1,050 chromosomes, 133 T alleles)
was 12.67%, comparedwith an allele frequency of 8.64%
in 1,961 white control individuals (3,922 chromosomes,
339 T alleles; ) The risk allele was present inP ! .0001
22.8% of individuals with SLE, compared with 16.7%
of control individuals.
After adjustment for age and sex, we found no signiﬁ-
cant differences in frequencies of lupus subphenotypes
in subjects carrying one or more copies of the risk allele,
compared with individuals lacking the risk allele (as de-
ﬁned by the criteria used to diagnose SLE: malar rash,
discoid rash, arthritis, oral ulcers, serositis, renal disorder,
CNS disorder, hematologic disorder, anti-dsDNA, Sm or
anticardiolipin antibodies, and antinuclear antibodies).
The risk allele is less common in African American and
Hispanic/Latino populations than in North American
whites (Begovich et al. 2004), and our current collection
is not sufﬁciently powered to assess the possible inﬂuence
of R620W on SLE in these populations. Finally, we note
that there is currently no signiﬁcant evidence for linkage
at the 1p13 locus in the Minnesota family collection
(Gaffney et al. 2000). The transmission/disequilibrium
test (TDT), when applied to combined cohorts A and
C, showed 70 transmissions and 57 nontransmissions of
the T allele from heterozygous founders, a result that
did not reach signiﬁcance ( ). The transmission:Pp .22
nontransmission ratio of 1.23 is consistent with the OR
for this allele (1.37 for C/T heterozygotes). Given an
allele frequency in the subject population of 12.67% and
ORs of 1.37 (1.07–1.75) for C/T heterozygotes and 4.37
(1.98–9.65) for T/T homozygotes, 229 trios (66–2,578)
are required for 80% power at . Thus, the currentP ! .05
trio collection is likely underpowered to detect the effect
by TDT.
These data, together with the recent evidence for as-
sociation of R620W with T1D (Bottini et al. 2004) and
RA (Begovich et al. 2004), suggest that the minor allele
is a potent genetic risk factor for both organ-speciﬁc
(T1D) and systemic (RA and SLE) autoimmune syn-
dromes. Knockout mice deﬁcient for PTPN22 show se-
lective dysregulation in the effector/memory T-cell com-
partment, with hyperproliferation and exaggerated early
signaling responses in restimulated T cells, comparedwith
essentially normal responses in naive T cells (Hasegawa
et al. 2004). PTPN22 knockouts also demonstrated high-
level spontaneous germinal center formation and ele-
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vated titers of T-dependent antibodies IgG1 and IgG2a
(Hasegawa et al. 2004). All three of the human auto-
immune diseases shown to date to be associated with
PTPN22 R620W are characterized by the production of
autoantibodies (anti-GADAbs in T1D, anti-citrullineAbs
and rheumatoid factor in RA, and a vast array of auto-
antibodies in SLE), and the appearance of these antibodies
often predates clinical disease (Arbuckle et al. 2003;Ran-
tapaa-Dahlqvist et al. 2003). We speculate that the 620W
variant of PTPN22 may predispose individuals to auto-
immunity by facilitating the generation of certain disease-
associated autoantibodies, thereby contributing to disease
onset and progression.
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